Belite Bio (BLTE)

• Market cap: $2B
• 1 day: -4.17%
• 5 days: -1.83%
• 1 month: -2.20%
• 3 months: -14.30%
• 6 months: -4.48%
• Year to date: -8.05%
• 1 year: 18.86%
• 5 years: 462.32%
• 10 years: 462.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 25

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.46% less ownership

Funds ownership: 0.92% [Q4 2024] → 0.46% (-0.46%) [Q1 2025]

18% less funds holding

Funds holding: 22 [Q4 2024] → 18 (-4) [Q1 2025]

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

44% less capital invested

Capital invested by funds: $17.8M [Q4 2024] → $9.91M (-$7.91M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $80 34% upside
• Avg. target: $90 51% upside
• High target: $100 68% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen	68% upside $100	Buy Reiterated	15 May 2025
Benchmark Bruce Jackson	34% upside $80	Buy Reiterated	26 Mar 2025